Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug
Lotus Pharmaceuticals, Inc. reported that the company has received approval from the regulatory authorities in China to begin Phase I clinical trials for one of its drug candidates - R-Bambuterol Hydrochloride, which is used to treat Asthma Lotus Pharmaceuticals, Inc. said that the Phase I trials would include studying the tolerance of the drug in humans, and pharmacokinetics, which is the study of what the body does to the drug after dosage. Lotus Pharmaceuticals, Inc. said that research conducted by a third party indicated that the Asthma market in China is approximately $300 million annually, and as many as 40…